ClearTrial and Top 20 Sponsor Company to Present Case Study on Effective Clinical Trial Forecasting and Budgeting at Leading European ConferenceClearTrial industry expert to join ClearTrial customer on the podium to demonstrate ways to achieve greater speed and accuracy in clinical trial planning London, UK – 20 September, 2010
ClearTrial, the leading provider of Clinical Trial Operations (CTO) software, announced today that the company has been asked to present – together with a Top 20 biopharmaceutical sponsor – a case study entitled "Faster, More Accurate Clinical Trial Forecasting and Budgeting." The two companies will present the case study at the Informa Budgeting, Forecasting and Cost Management conference on 22-23 September in London.
"We're pleased to be able to present with a ClearTrial customer at this prestigious European event," noted Andy Grygiel, Vice President of Marketing and Product Management for ClearTrial. "This case study represents just one example of how ClearTrial software is helping biopharmaceutical and medical device companies worldwide gain greater efficiency in clinical development by reducing planning cycle-times and reducing costs, while maintaining study feasibility." ClearTrial is the leading provider of Clinical Trial Operations (CTO) software, an integrated system for clinical operations planning, forecasting, outsourcing, and project tracking. ClearTrial’s award-winning software helps life sciences companies streamline their clinical operations from Plan to Payment™ without sacrificing quality of results, providing executives and functional leaders in clinical operations, resource planning, finance, outsourcing, and project management with a common platform that promotes speed, accuracy, and consistency throughout the organization. For more information visit http://www.cleartrial.com. ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners. For more information contact: Mike Lange |
